as 11-15-2024 11:35am EST
GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.
Founded: | 2003 | Country: | United States |
Employees: | N/A | City: | ROCKVILLE |
Market Cap: | 9.7M | IPO Year: | 2014 |
Target Price: | $12.00 | AVG Volume (30 days): | 60.7M |
Analyst Decision: | Hold | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.61 | EPS Growth: | N/A |
52 Week Low/High: | $0.14 - $3.53 | Next Earning Date: | 11-13-2024 |
Revenue: | $10,000 | Revenue Growth: | -86.67% |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
GLYC Breaking Stock News: Dive into GLYC Ticker-Specific Updates for Smart Investing
Associated Press Finance
2 days ago
PR Newswire
3 days ago
Business Wire
9 days ago
Simply Wall St.
16 days ago
TipRanks
16 days ago
MT Newswires
17 days ago
Business Wire
17 days ago
Business Wire
17 days ago
The information presented on this page, "GLYC GlycoMimetics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.